SyntaraASX:SNT -9.52% FCF Yield % is -31.30 as of Jun. 27, 2026. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Syntara ranks worse than 93.43% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Syntara's Trailing 12-Month Free Cash Flow is A$-11.67 Mil, and Market Cap is A$37.28 Mil. Therefore, Syntara's FCF Yield % for today is -31.30%.
The historical rank and industry rank for Syntara's FCF Yield % or its related term are showing as below:
ASX:SNT'
s FCF Yield % Range Over the Past 10 Years
Min: -89.31 Med: -23.69 Max: 14.75
Current: -31.3
During the past 13 years, the highest FCF Yield % of Syntara was 14.75%. The lowest was -89.31%. And the median was -23.69%.
ASX:SNT's FCF Yield % is ranked worse than 93.43% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs ASX:SNT: -31.30
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Syntara FCF Yield % Related Terms
Syntara FCF Yield % Historical Data
* Premium members only.
The historical data trend for Syntara's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syntara FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syntara's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Syntara's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syntara (ASX:SNT) has a FCF Yield % of -31.30 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Syntara and its competitors. According to the industry distribution chart, Syntara ranks #939 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 93.4%.
Is Syntara's FCF Yield % too high?
Syntara's current FCF Yield % is -31.30. Based on the distribution chart, Syntara ranks #939 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Syntara's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syntara ranks #939 out of 1005 companies for FCF Yield %. This places Syntara in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Syntara and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syntara's current FCF Yield % is -31.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syntara stock overvalued right now?
Syntara (ASX:SNT) has a current FCF Yield % of -31.30. The current FCF Yield % is -31.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Syntara (ASX:SNT), the current FCF Yield % is -31.30 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring and neuroinflammation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SNT has been successfully added to your 